ILE Isolagen

EXTON, Pa., Nov. 8 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) announced today its intention, subject to consultation with its UK workforce, to close Isolagen Europe Ltd., its UK operations. "The closure of the UK operations is a difficult decision based on a full business analysis," said Nicholas L. Teti, Isolagen Chairman and Chief Executive Officer. "While we value the hard work and commitment of our UK staff, sustaining further financial losses in the UK business is not in the Company's best interest." "The management and the Board have determined that the best use of resources is to focus on advancing the US pivotal Phase III clinical trial of the Isolagen Process for the treatment of certain facial wrinkles, and then, with regulatory agencies' agreement, initiate clinical studies in key strategic therapeutic and aesthetic areas," continued Mr. Teti. "We believe this action plan has the potential to create the greatest value for our shareholders." The proposed closure of Isolagen Europe Ltd. will affect approximately 80 positions in London, 21 from the Hammersmith management office, and 59 from the European manufacturing plant in Park Royal. About Isolagen, Inc. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: http://www.isolagen.com/. All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, including the expectation and belief that closing the UK facilities and deploying the Company's resources to advance the US pivotal Phase III clinical trial for the use of Isolagen(TM) Therapy for the treatment of certain facial wrinkles, and then, with regulatory agencies' agreement, the initiation of clinical studies in other therapeutic and aesthetic areas will create the greatest potential value for our shareholders, the information on which such expectations were based may change. Moreover, there can be no assurance that the requisite regulatory agency approvals will be forthcoming or that the trials will be successful. The forward-looking statements set forth above rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, as well as other public filings with the SEC since such date. DATASOURCE: Isolagen, Inc. CONTACT: US Media and Investors: Mike Beyer, of Sam Brown Inc., +1-773-463-4211, ; UK Media: Jennifer Burner, of Halpern PR, +44-20-7349-2517, ; both for Isolagen Web site: http://www.isolagen.com/

Copyright